Biowave

About:

Smarter neurotechnology medical devices that provide instant, long lasting pain relief.

Top Investors: Connecticut Innovations, Northstar Pain Management LLC

Description:

BioWave is a patented smarter pain blocking technology that delivers therapeutic electrical signals through skin into deep tissue right to the surface of pain fibers. The electrical field that forms around the pain fibers blocks the transmission of pain signals to the brain. The mechanism of action is similar to a chemical anesthetic like Novocain, except BioWave is blocking the transmission of the pain signal electrically instead of chemically. Because the pain signal is blocked at the nerve inside the body, a 30 minute treatment can provide up to 24 hours of continued pain relief. And there is a cumulative benefit with multiple treatments. BioWave manufactures and sells 3 medical device systems, BioWavePRO (Rx), BioWaveHOME (Rx) and BioWaveGO (OTC) and two types of disposables - sterile single use percutaneous electrodes and reusable noninvasive electrodes. More information is available at biowave.com.

Total Funding Amount:

$3.1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Norwalk, Connecticut, United States

Founded Date:

2000-01-03

Contact Email:

info(AT)biowave.com

Founders:

Bradford Siff

Number of Employees:

11-50

Last Funding Date:

2020-01-01

IPO Status:

Private

Industries: